February 11, 2019 7:50am

Out and about:  blue bird bio (BLUE) plays musical chairs in the executive ranks. Intellia Therapeutics (NTLA) has a licensing arbitration with Caribou Biosciences in their hands by major shareholder; the issue for the stock is Caribou (private) has been reducing its holdings from 9.2% to 5.8% to supplement their funding

Pre-open indications:  1 SELL (maintained) and 3 TRADEs


Once we get through quarterly LPS (loss-per-share) financial results <notice I didn’t say – earnings season, it will be easier for investors to possibly recognize a short or a near-term view; but my fear is that Q4 numbers aren't going to look much better than the Q3/18 numbers.

Members only. Please login.